person · Reporting owner
MAZELSKY JONATHAN JAY
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | September 30, 2026 | October 03, 2026 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director · President and CEO | February 26, 2026 | March 02, 2026 |
| INSULET CORPPODD · Entity 3516 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DENTSPLY SIRONA Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock (Directors' Deferred Compensation) DDCSEC Table II · derivative / convertible security | Direct | 23,345.1175 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 3,323.4332 · Balance 23,345.1175 F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2: Comprised of phantom stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director.
F2: Comprised of phantom stock.
IDEXX LABORATORIES INC /DE
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,803.302 |
Ending reported balance
After 2026-02-27 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-02-26 · Exercise / conversion · Acquired 23,326 · Balance 106,932.302 Row 2 · 2026-02-26 · Sale · Disposed 1,281 · Balance 105,651.302 F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2026-02-26 · Sale · Disposed 1,095 · Balance 104,556.302 F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 4 · 2026-02-26 · Sale · Disposed 1,669 · Balance 102,887.302 F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 5 · 2026-02-26 · Sale · Disposed 1,171 · Balance 101,716.302 F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 6 · 2026-02-26 · Sale · Disposed 1,111 · Balance 100,605.302 F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 7 · 2026-02-26 · Sale · Disposed 1,488 · Balance 99,117.302 F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 8 · 2026-02-26 · Sale · Disposed 1,343 · Balance 97,774.302 F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 9 · 2026-02-26 · Sale · Disposed 2,860 · Balance 94,914.302 F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 10 · 2026-02-26 · Sale · Disposed 3,660 · Balance 91,254.302 F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 11 · 2026-02-26 · Sale · Disposed 2,859 · Balance 88,395.302 F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 12 · 2026-02-26 · Sale · Disposed 1,200 · Balance 87,195.302 F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 13 · 2026-02-26 · Sale · Disposed 1,000 · Balance 86,195.302 F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 14 · 2026-02-26 · Sale · Disposed 2,589 · Balance 83,606.302 F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 15 · 2026-02-27 · Exercise / conversion · Acquired 197 · Balance 83,803.302 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $141.60 · Expires 2027-02-13 | Direct | 0 |
Reported balance
After 2026-02-26 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-02-26 · Exercise / conversion · Disposed 23,326 · Balance 0 F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $505.53 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-02-27 · Exercise / conversion · Disposed 197 · Balance 0 F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018.
F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.
INSULET CORP
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,496 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 141 · Balance 1,496 F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2024 Filed Feb 9, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 12,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0000874716-24-000014 · wk-form4_1707516010.xml · derivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,260 Underlying: Common Stock · 12,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in four annual installments beginning February 14, 2017. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 705 | $575.48 | $405,711.21 |
DisclosureSEC source: 0000874716-24-000014 · wk-form4_1707516010.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,246.5926 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $575.35 to a high of $575.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,353 | $574.75 | $777,638.78 |
DisclosureSEC source: 0000874716-24-000014 · wk-form4_1707516010.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,951.5926 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $574.29 to a high of $575.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 462 | $573.19 | $264,814.29 |
DisclosureSEC source: 0000874716-24-000014 · wk-form4_1707516010.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,304.5926 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $573.14 to a high of $573.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,124 | $572.53 | $2,361,094.34 |
DisclosureSEC source: 0000874716-24-000014 · wk-form4_1707516010.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,766.5926 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $572.13 to a high of $573.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,356 | $571.71 | $3,062,060.55 |
DisclosureSEC source: 0000874716-24-000014 · wk-form4_1707516010.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,890.5926 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $571.12 to a high of $572.11 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 12,000 | $67.85 | $814,200.00 |
DisclosureSEC source: 0000874716-24-000014 · wk-form4_1707516010.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,246.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 13.247 shares purchased under the Issuer Employee Stock Purchase Plan on December 29, 2023. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 19:04 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 6.4726 | $36.80 | $238.19 |
DisclosureSEC source: 0001127602-24-001316 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,707.624 Underlying: Common Stock · 6.4726 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 19:04 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 21.479 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-001316 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,481.723 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 22:43 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 702.7117 | $35.58 | $25,002.48 |
DisclosureSEC source: 0001127602-24-000158 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701.1514 Underlying: Common Stock · 702.7117 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 13,424 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0000874716-23-000141 · wk-form4_1701900077.xml · derivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,424 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 13,424 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,324 | $513.51 | $679,887.24 |
DisclosureSEC source: 0000874716-23-000141 · wk-form4_1701900077.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,233.3456 F3 · balance_after: Represents the weighted average price of the shares sold ranging from a low of $513.36 to a high of $513.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,804 | $512.95 | $2,977,161.80 |
DisclosureSEC source: 0000874716-23-000141 · wk-form4_1701900077.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,557.3456 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $512.35 to a high of $513.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 13,424 | $79.54 | $1,067,744.96 |
DisclosureSEC source: 0000874716-23-000141 · wk-form4_1701900077.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,361.3456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on September 29, 2023. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 21:05 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 4.5312 | $30.71 | $139.15 |
DisclosureSEC source: 0001127602-23-025916 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 998.4397 Underlying: Common Stock · 4.5312 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 21:05 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 22.287 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-025916 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,460.244 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 20:13 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 729.2413 | $34.28 | $24,998.39 |
DisclosureSEC source: 0001127602-23-024982 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993.9085 Underlying: Common Stock · 729.2413 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 13,424 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0000874716-23-000117 · wk-form4_1693947669.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,424 Underlying: Common Stock · 13,424 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 13,424 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 13,424 | $512.01 | $6,873,266.54 |
DisclosureSEC source: 0000874716-23-000117 · wk-form4_1693947669.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,925.3456 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $512.00 to a high of $512.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 13,424 | $79.54 | $1,067,744.96 |
DisclosureSEC source: 0000874716-23-000117 · wk-form4_1693947669.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,349.3456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-23-000106 · wk-form4_1691531933.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,443 Underlying: Common Stock · 384 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 170 | $504.08 | $85,693.60 |
DisclosureSEC source: 0000874716-23-000106 · wk-form4_1691531933.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,925.3456 F2 · price: Closing price of Issuer common stock on NASDAQ market on August 4, 2023. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 384 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000106 · wk-form4_1691531933.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,095.3456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:18 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 0.8976 | $41.14 | $36.93 |
DisclosureSEC source: 0001127602-23-020835 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264.6672 Underlying: Common Stock · 0.8976 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:18 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 18.957 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020835 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,437.957 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 21:08 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 263.7696 | $39.58 | $10,440.00 |
DisclosureSEC source: 0001127602-23-019569 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263.7696 Underlying: Common Stock · 263.7696 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock and accrued dividends. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:56 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 5,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016976 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,419 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| May 18, 2023 Filed May 19, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000084 · wf-form4_168453026450198.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,699.3456 Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0000874716-23-000038 · wf-form4_168332400555957.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 560 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable on the fifth anniversary of the date of grant. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 560 | $178.26 | $99,825.60 |
DisclosureSEC source: 0000874716-23-000038 · wf-form4_168332400555957.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,301.3456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 14.7030 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 959 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · derivative · entry 11 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,827 Underlying: Common Stock · 959 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · derivative · entry 10 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,786 Underlying: Common Stock · 689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F6 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 974 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · derivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,475 Underlying: Common Stock · 974 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F6 · price: Not applicable. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · derivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,449 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F6 · price: Not applicable. F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · derivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,884 Underlying: Common Stock · 504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F6 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,657 | $503.65 | $834,548.05 |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,726.6426 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 959 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,383.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 689 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,424.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 974 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,735.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,761.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:52 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 504 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003219 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,326.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 4,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,388 Underlying: Common Stock · 4,398 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F6 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantPremium Non-Qualified Stock Option (right-to-buy) · Derivative | 12,181 | Not disclosed Strike: $572.04 | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,181 Underlying: Common Stock · 12,181 shares Expires 2033-02-07 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option at a 115% premium to the closing price of Issuer common stock on the NASDAQ Global Select Market on February 8, 2023 to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 21,256 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,256 Underlying: Common Stock · 21,256 shares Expires 2033-02-07 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,998 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · derivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,998 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 9,499 shares of Issuer common stock that became exercisable for 8,244 shares in four equal annual installments beginning February 14, 2015 and for the remaining 1,255 shares on February 14, 2019 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 600 | $435.88 | $261,526.50 |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,804.6426 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $435.77 to a high of $436.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,543 | $435.07 | $1,106,386.06 |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,404.6426 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $434.70 to a high of $435.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,385 | $434.26 | $2,772,759.68 |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,947.6426 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $433.69 to a high of $434.685 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 972 | $433.37 | $421,239.63 |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,332.6426 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $432.67 to a high of $433.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.